Clinical Trial Update: JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC [Phase 3]

View source ↗

Summary

Phase 3 trial of JNJ-90301900 (NBTXR3) activated by radiotherapy with or without cetuximab for locally advanced head and neck squamous cell carcinoma. The study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Cetuximab (cetuximab)
• JNJ-90301900 (NBTXR3) (NBTXR3)

Snippet

Sponsor: Johnson & Johnson Enterprise Innovation Inc. | Conditions: Locally Advanced Head and Neck Squamous Cell Carcinoma, Aged | Phase 3 | Status: RECRUITING